目的 探討復(fù)明片聯(lián)合地夸磷索鈉滴眼液治療白內(nèi)障術(shù)后干眼癥的臨床療效。方法 選取2023年5月—2024年5月在青海紅十字醫(yī)院治療的108例白內(nèi)障術(shù)后干眼癥患者，利用隨機(jī)數(shù)字表法將患者分為對(duì)照組（52例）和治療組（56例）。對(duì)照組給予地夸磷索鈉滴眼液，1滴/次，6次/d。治療組在對(duì)照組基礎(chǔ)上口服復(fù)明片，5片/次，3次/d。兩組患者連續(xù)用藥30 d。觀察兩組患者臨床療效，比較治療前后兩組患者癥狀緩解時(shí)間，淚液分泌測(cè)試（SIT）、淚膜破裂時(shí)間（BUT）、角膜熒光素染色（FL）評(píng)分，淚液炎癥細(xì)胞因子白細(xì)胞介素-1β（IL-1β）、腫瘤壞死因子-α（TNF-α）和白細(xì)胞介素-6（IL-6），及視功能相關(guān)生命質(zhì)量量表（NEI-VFQ-25）評(píng)分。結(jié)果 治療后，治療組患者的總有效率為96.43%，明顯高于對(duì)照組的84.61%，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P＜0.05）。治療后，治療組患者癥狀緩解時(shí)間均顯著短于對(duì)照組（P＜0.05），治療后，兩組SIT和BUT均顯著提高，且FL評(píng)分顯著降低（P＜0.05），且治療組患者上述指標(biāo)優(yōu)于對(duì)照組（P＜0.05）。治療后，兩組淚液中IL-1β、TNF-α和IL-6的濃度均降低（P＜0.05），并且治療組淚液炎癥細(xì)胞因子濃度顯著低于對(duì)照組（P＜0.05）。治療后，兩組NEI-VFQ-25評(píng)分中GH、GV、OP、NV、DV、SF、MH、RD、Dep、Dri評(píng)分均高于治療前（P＜0.05），且治療組優(yōu)于對(duì)照組（P＜0.05）。結(jié)論 復(fù)明片聯(lián)合地夸磷索鈉滴眼液治療白內(nèi)障術(shù)后干眼癥具有顯著療效，能夠有效緩解臨床癥狀，改善淚液分泌、淚膜穩(wěn)定性，降低淚液炎癥因子水平，提高視功能相關(guān)生命質(zhì)量，且具有較高的安全性。

Objective To explore the clinical efficacy of Fuming Tablets combined with Diquafosol Sodium Eye Drops in treatment of post-cataract surgery dry eye syndrome. Methods Patients (108 cases) with post-cataract surgery dry eye syndrome in the Qinghai Red Cross Hospital from May 2023 to May 2024 were divided into control (52 cases) and treatment (56 cases) group by random number table method. Patient in the control group were administered with Diquafosol Sodium Eye Drops, 1 drop/time, six times daily. Patient in the treatment group were po administered with Fuming Tablets on the basis of the control group, 5 tablets/time, three times daily. Patient in two groups were treated for 30 d. After treatment, the clinical evaluations were evaluated, and the symptom relief time, the scores of SIT, BUT and FL, inflammatory cytokines IL-1β, TNF-α and IL-6 in tears, and NEI-VFQ-25 scores in two groups before and after treatment were compared. Results After treatment, the total effective rate of patients in the treatment group was 96.43%, which was significantly higher than that of the control group (84.61%), the difference between the two groups was statistically significant (P < 0.05). After treatment, the symptom relief time of patients in the treatment group was significantly shorter than that in the control group (P < 0.05). After treatment, SIT and BUT in two groups were significantly improved, but FL scores were significantly reduced (P < 0.05), and the levels of patients in the treatment group were better than those in the control group (P < 0.05). After treatment, the concentrations of IL-1β, TNF-α and IL-6 in tears were decreased in two groups (P < 0.05), and the concentration of inflammatory cytokines in tears in the treatment group was significantly lower than that in the control group (P < 0.05). After treatment, GH, GV, OP, NV, DV, SF, MH, RD, Dep, Dri of NEI-VFQ-25 scores in two groups were higher than before treatment (P < 0.05), and the treatment group was higher than the control group (P < 0.05). Conclusion Fuming Pian combined with Diquafosol Sodium Eye Drops is highly effective in treating post-cataract surgery dry eye syndrome, which can effectively relieve clinical symptoms, improve tear secretion, tear film stability, lower inflammatory cytokine levels, improve vision-related quality of life, and has high safety.

R988.1

青海省衛(wèi)生健康委員會(huì)指導(dǎo)性計(jì)劃項(xiàng)目（2023-wjzdx-09）